November 24, 2016 - By Louis Casey · 0 Comments
The stock of Actinium Pharmaceuticals Incorporated (NYSEMKT:ATNM) registered a decrease of 0.04% in short interest. ATNM’s total short interest was 2.17 million shares in November as published by FINRA. Its down 0.04% from 2.17M shares, reported previously. With 470,700 shares average volume, it will take short sellers 5 days to cover their ATNM’s short positions. The short interest to Actinium Pharmaceuticals Incorporated’s float is 4.97%. The stock increased 3.05% or $0.03 on November 23, hitting $1.01. About 115,194 shares traded hands. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) has declined 50.00% since April 22, 2016 and is downtrending. It has underperformed by 55.41% the S&P500.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm engaged in developing cancer treatments. The company has a market cap of $53.57 million. The Firm is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. It currently has negative earnings. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Insitutional Activity: The institutional sentiment increased to 2.14 in Q2 2016. Its up 0.81, from 1.33 in 2016Q1. The ratio improved, as 6 funds sold all Actinium Pharmaceuticals Inc shares owned while 3 reduced positions. 2 funds bought stakes while 10 increased positions. They now own 3.17 million shares or 14.30% more from 2.77 million shares in 2016Q1.
Blackrock Advisors Limited Liability Corporation accumulated 0% or 8,447 shares. Blackrock Management Ltd has 0% invested in the company for 6,869 shares. Vanguard holds 0% of its portfolio in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) for 1.58 million shares. Blackrock Institutional Tru Company Na accumulated 0% or 462,683 shares. Gsa Capital Prtnrs Ltd Liability Partnership holds 0.01% of its portfolio in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) for 139,400 shares. Raymond James Financial Ser Advsrs Inc holds 17,200 shares or 0% of its portfolio. Hartford Financial Inc holds 0% or 2,000 shares in its portfolio. Financial Bank Of New York Mellon Corporation last reported 96,807 shares in the company. Natl Bank Of Montreal Can holds 2,500 shares or 0% of its portfolio. Moreover, Bridgeway Cap Management has 0.01% invested in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) for 240,200 shares. Moreover, Nomura has 0% invested in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) for 23,954 shares. Morgan Stanley has 0% invested in the company for 76,904 shares. Moreover, Gru One Trading Ltd Partnership has 0% invested in Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) for 3,045 shares. State Street Corp accumulated 0% or 11,700 shares. Da Davidson Communication reported 90,000 shares or 0% of all its holdings.
Insider Transactions: Since May 25, 2016, the stock had 0 insider purchases, and 9 insider sales for $1.22 million net activity. The insider Memorial Sloan-Kettering Cancer Center sold 3,100 shares worth $5,581.
Out of 2 analysts covering Actinum Pharma (NYSEMKT:ATNM), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Actinum Pharma has been the topic of 2 analyst reports since October 15, 2015 according to StockzIntelligence Inc. FBR Capital initiated Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) rating on Thursday, October 15. FBR Capital has “Outperform” rating and $12.0 price target. Roth Capital initiated it with “Buy” rating and $5 target price in Thursday, August 25 report.
Actinium Pharmaceuticals, Inc. (Actinium), incorporated on March 20, 2013, is a clinical-stage biopharmaceutical firm engaged in developing cancer treatments. The Firm is engaged in developing therapies for diseases using its alpha particle immunotherapy (APIT) platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Actinium’s products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. The Firm is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center (FHCRC).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey